17:02 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; high throughput screening A high throughput, CRISPR interference (CRISPRi)-based method of mapping genetic interactions could help identify new drug targets for cancer and genetic disorders. The method involves: selecting sgRNAs against genes identified...
13:22 , Jun 29, 2018 |  BioCentury  |  Finance

Nailing down NLRP3

The next-generation chemistry behind its NLRP3 inhibitors enabled inflammasome play NodThera Ltd. to close a £28 million ($37 million) series A round led by Sofinnova Partners and 5AM Ventures. F-Prime Capital Partners and founding investor...
01:06 , Jan 10, 2018 |  BC Extra  |  Company News

GSK confirms management overhaul

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has replaced about 40% of its top management team since CEO Emma Walmsley took the helm in April 2017, the pharma confirmed to BioCentury Tuesday. GSK spokesperson Sarah Spencer told BioCentury the...
22:05 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Candida Cell culture and mouse studies suggest inhibiting Candida MIR1 could help treat azole-resistant oropharyngeal candidiasis. In azole-resistant strains of C. albicans isolated from an HIV-infected patient and in four azole-resistant strains of C. auris,...
21:41 , Nov 30, 2017 |  BC Innovations  |  Strategy

Doctors in the house

While academic partnerships have become par for the course in pharma, GSK is going a step beyond the standard model of external alliances by bringing professors in-house with virtually unrestricted access to its activities. The...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
22:32 , Jun 22, 2017 |  BC Innovations  |  Product R&D

Bispecific redirection

With an unusual spinout from a startup and BiTE pioneer Patrick Baeuerle on board, MPM Capital is using his next-generation technology to stake new territory in the field. Through Harpoon Therapeutics Inc. and the recently...
22:18 , Mar 24, 2017 |  BioCentury  |  Emerging Company Profile

Specificity in the inflammasome

Inflazome Ltd. is springboarding off an old Pfizer Inc. compound to design a collection of new inflammasome inhibitors targeted to specific cells and tissues to treat diseases including multiple sclerosis, Alzheimer’s disease and gout. The...
01:19 , Jan 20, 2017 |  BC Extra  |  Company News

GSK names Miels president of global pharmaceuticals

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) named Luke Miels president of global pharmaceuticals. Miels will succeed Abbas Hussain, who will leave the company later this year. Hussain has held the position since October 2014. Miels is EVP of...
07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc.'s anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical and...